{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:31:16Z","timestamp":1780669876608,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201000059C"],"award-info":[{"award-number":["HHSO100201000059C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.06.017","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T07:22:59Z","timestamp":1656314579000},"page":"5544-5555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays"],"prefix":"10.1016","volume":"40","author":[{"given":"Jon","family":"Inglefield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Catania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Minang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Baranji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarl","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee","family":"Look","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7198","key":"10.1016\/j.vaccine.2022.06.017_b0005","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.017_b0010","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/eji.200838648","article-title":"Alum adjuvanticity: unraveling a century old mystery","volume":"38","author":"De Gregorio","year":"2008","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.017_b0015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.017_b0020","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.181.6.3755","article-title":"Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome","volume":"181","author":"Kool","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.017_b0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.06.017_b0030","first-page":"25","article-title":"Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant","volume":"51","author":"Chang","year":"1997","journal-title":"PDA J Pharm Sci Technol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.017_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0264-410X(95)80009-3","article-title":"Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants","volume":"13","author":"Al-Shakhshir","year":"1995","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2022.06.017_b0040","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.017_b0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/jps.22282","article-title":"Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines","volume":"100","author":"Ausar","year":"2011","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.017_b0050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/jps.23039","article-title":"The role of adjuvant in mediating antigen structure and stability","volume":"101","author":"Braun","year":"2012","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.017_b0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijbiomac.2009.04.008","article-title":"Effects of immobilization onto aluminum hydroxide particles on the thermally induced conformational behavior of three model proteins","volume":"45","author":"Bai","year":"2009","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.017_b0060","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ab.2006.01.008","article-title":"Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations","volume":"351","author":"Dong","year":"2006","journal-title":"Anal Biochem"},{"issue":"27","key":"10.1016\/j.vaccine.2022.06.017_b0065","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1073\/pnas.1107941108","article-title":"Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88","volume":"108","author":"Seubert","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.017_b0070","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1073\/pnas.1012455108","article-title":"Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59","volume":"108","author":"Ellebedy","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2022.06.017_b0075","doi-asserted-by":"crossref","unstructured":"Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006;72:1102-13. https:\/\/dx.doi.org\/S0006-2952(06)00427-8 [pii];10.1016\/j.bcp.2006.07.010 [doi].","DOI":"10.1016\/j.bcp.2006.07.010"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.017_b0080","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1038\/cti.2016.22","article-title":"Toll-like receptors: the Swiss army knife of immunity and vaccine development","volume":"5","author":"Dowling","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.017_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1412s109","article-title":"Toll\u2010Like Receptors","volume":"109","author":"Takeda","year":"2015","journal-title":"Current Protocols in Immunology"},{"issue":"21-22","key":"10.1016\/j.vaccine.2022.06.017_b0090","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/S0264-410X(03)00109-9","article-title":"Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants","volume":"21","author":"Jendrek","year":"2003","journal-title":"Vaccine"},{"issue":"15-16","key":"10.1016\/j.vaccine.2022.06.017_b0095","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.vaccine.2003.10.040","article-title":"Distribution of adsorbed antigen in mono-valent and combination vaccines","volume":"22","author":"Morefield","year":"2004","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.017_b0100","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.017_b0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/CVI.00696-15","article-title":"Humoral and cell-mediated immune responses to alternate booster schedules of anthrax vaccine adsorbed in humans","volume":"23","author":"Quinn","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.017_b0110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J Appl Microbiol"},{"issue":"3-4","key":"10.1016\/j.vaccine.2022.06.017_b0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.017_b0120","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.017_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jim.2007.04.003","article-title":"Formulation of vaccines containing CpG oligonucleotides and alum","volume":"323","author":"Aebig","year":"2007","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.017_b0130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3024.1982.tb00445.x","article-title":"A comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse","volume":"4","author":"Bomford","year":"1982","journal-title":"Parasite Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.017_b0135","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.vaccine.2013.01.012","article-title":"A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen","volume":"31","author":"Gwinn","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.017_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2004.10.007","article-title":"Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain","volume":"38","author":"Flick-Smith","year":"2005","journal-title":"Microb Pathog"},{"issue":"30","key":"10.1016\/j.vaccine.2022.06.017_b0145","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.017_b0150","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.017_b0155","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.4049\/jimmunol.178.4.2415","article-title":"TLR9 signaling in B cells determines class switch recombination to IgG2a","volume":"178","author":"Jegerlehner","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.017_b0160","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/IAI.72.1.584-588.2004","article-title":"Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen","volume":"72","author":"Coban","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2022.06.017_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4161\/hv.5.2.6521","article-title":"Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice","volume":"5","author":"Thomas","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2022.06.017_b0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1574-695X.2001.tb00535.x","article-title":"CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice","volume":"32","author":"Weeratna","year":"2001","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.017_b0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.intimp.2012.05.003","article-title":"MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice","volume":"13","author":"Yang","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.017_b0180","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/eji.200324736","article-title":"CpG DNA redirects class-switching towards \u201cTh1-like\u201d Ig isotype production via TLR9 and MyD88","volume":"34","author":"Lin","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2022.06.017_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166322","article-title":"T cell production of IFNgamma in response to TLR7\/IL-12 stimulates optimal B cell responses to viruses","volume":"11","author":"Rubtsova","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.017_b0190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-3083.1990.tb02826.x","article-title":"Regulation of isotype immunoglobulin production by adjuvants in vivo","volume":"31","author":"Karagouni","year":"1990","journal-title":"Scand J Immunol"},{"issue":"31","key":"10.1016\/j.vaccine.2022.06.017_b0195","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1016\/j.vaccine.2009.04.047","article-title":"Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice","volume":"27","author":"Quintilio","year":"2009","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2022.06.017_b0200","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.vaccine.2008.02.063","article-title":"Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection","volume":"26","author":"Bungener","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.017_b0205","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/jps.24573","article-title":"In vivo analysis of the potency of silicone oil microdroplets as immunological adjuvants in protein formulations","volume":"104","author":"Chisholm","year":"2015","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.017_b0210","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1006\/cimm.2000.1689","article-title":"Adjuvant activities of immune response modifier R-848: comparison with CpG ODN","volume":"204","author":"Vasilakos","year":"2000","journal-title":"Cell Immunol"},{"issue":"20-21","key":"10.1016\/j.vaccine.2022.06.017_b0215","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/S0264-410X(98)00499-X","article-title":"Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice","volume":"17","author":"Katayama","year":"1999","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2022.06.017_b0220","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1016\/j.vaccine.2014.08.059","article-title":"OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis","volume":"32","author":"Yanase","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.017_b0225","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.intimp.2005.01.002","article-title":"Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice","volume":"5","author":"Li","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2022.06.017_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/280238","article-title":"Adsorption of toll-like receptor 4 agonist to alum-based tetanus toxoid vaccine dampens pro-T helper 2 activities and enhances antibody responses","volume":"2015","author":"Bortolatto","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2022.06.017_b0235","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid","volume":"15","author":"Cribbs","year":"2003","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2022.06.017_b0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4168\/aair.2016.8.3.264","article-title":"CpG oligodeoxynucleotide inhibits cockroach-induced asthma via induction of IFN-gamma(+) Th1 cells or Foxp3(+) regulatory T cells in the lung","volume":"8","author":"Kim","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"issue":"26","key":"10.1016\/j.vaccine.2022.06.017_b0245","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1073\/pnas.95.26.15553","article-title":"CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice","volume":"95","author":"Millan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"10.1016\/j.vaccine.2022.06.017_b0250","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3M\u2013052: an imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2022.06.017_b0255","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1182\/blood-2011-09-378182","article-title":"The Ets-1 transcription factor is required for Stat1-mediated T-bet expression and IgG2a class switching in mouse B cells","volume":"119","author":"Nguyen","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.017_b0260","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/mnfr.201200410","article-title":"Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice","volume":"57","author":"Kulis","year":"2013","journal-title":"Mol Nutr Food Res"},{"issue":"15","key":"10.1016\/j.vaccine.2022.06.017_b0265","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1128\/JVI.00339-16","article-title":"Effects of MF59 adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells","volume":"90","author":"Ko","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.06.017_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101474","article-title":"Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Abeta antibodies induced by multimeric protein antigen (1\u201311)E2, preserving the Igg1-skewed isotype distribution","volume":"9","author":"Mantile","year":"2014","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:59Z","timestamp":1759403759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":54,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22007642"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}